Factor XI antisense oligonucleotide for prevention of venous thrombosis. - Wikidata - wikimedia - TriplyDB

Factor XI antisense oligonucleotide for prevention of venous thrombosis.

Factor XI antisense oligonucleotide for prevention of venous thrombosis.

http://www.wikidata.org/entity/Q35200286

about

Factor XI and contact activation as targets for antithrombotic therapy Integrated Safety Assessment of 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers The Effects of 2'-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials.Selection and characterization of a DNA aptamer inhibiting coagulation factor XIa.Collateral Lethality: A new therapeutic strategy in oncology Allosteric inhibition of factor XIa. Sulfated non-saccharide glycosaminoglycan mimetics as promising anticoagulants.Differential Kinetics of Coagulation Factors and Natural Anticoagulants in Patients with Liver Cirrhosis: Potential Clinical Implications The polyphosphate-factor XII pathway drives coagulation in prostate cancer-associated thrombosis.FXIa and platelet polyphosphate as therapeutic targets during human blood clotting on collagen/tissue factor surfaces under flow Factor XIa and Thrombin Generation Are Elevated in Patients with Acute Coronary Syndrome and Predict Recurrent Cardiovascular Events Genetic diminution of circulating prothrombin ameliorates multiorgan pathologies in sickle cell disease mice Platelet-Derived Short-Chain Polyphosphates Enhance the Inactivation of Tissue Factor Pathway Inhibitor by Activated Coagulation Factor XI.Identification and characterization of modified antisense oligonucleotides targeting DMPK in mice and nonhuman primates for the treatment of myotonic dystrophy type 1.Prospective study of circulating factor XI and incident venous thromboembolism: The Longitudinal Investigation of Thromboembolism Etiology (LITE).Lack of association of plasma factor XI with incident stroke and coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study Long noncoding RNAs in cancer: from function to translation.Suppressing angiotensinogen synthesis attenuates kidney cyst formation in a Pkd1 mouse model.Directed Alternative Splicing in Nijmegen Breakage Syndrome: Proof of Principle Concerning Its Therapeutical Application Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans Coagulation Factor XI Promotes Distal Platelet Activation and Single Platelet Consumption in the Bloodstream Under Shear Flow.Factor XI Deficiency Protects Against Atherogenesis in Apolipoprotein E/Factor XI Double Knockout Mice.A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation.Stabilin-1 and Stabilin-2 are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides (ASOs) in the liver.How it all starts: Initiation of the clotting cascade.Long Noncoding RNAs in Cancer Pathways Factor XI as a Therapeutic Target.Factor XIa inhibitors: A review of the patent literature.Why factor XI deficiency is a clinical concern.The delivery of therapeutic oligonucleotides AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.Factors XI and XII as Targets for New Anticoagulants.Antisense Oligonucleotides: Treatment Strategies and Cellular Internalization.Anticoagulation therapy in 2015: where we are and where we are going.Acute and persistent platelet and coagulant activities in atherothrombosis.Medical device-induced thrombosis: what causes it and how can we prevent it?Factor XII: a novel target for safe prevention of thrombosis and inflammation.New products for the treatment of haemophilia.Prothrombotic aspects of sickle cell disease.Epigenetics and allergy: from basic mechanisms to clinical applications.Injection site reactions after subcutaneous oligonucleotide therapy

P2860

Q27024190-37ABB3E1-5BF1-490E-ADFF-EB99F4E95A4A Q28821280-B73D5D82-4635-4216-909F-AA1ED483FD64 Q33438876-D82DE8F7-0518-4679-972E-59CA4984849A Q33704680-3FBAB076-A389-4A55-8BC5-67F892FFFAAB Q34513800-AF2B8E23-6B48-44EF-A149-ABD1E2556CD3 Q35920828-847ED015-CEAF-4052-9C32-A8F297F9AD85 Q36015509-2D21177E-852A-4D9F-8A7A-261669C4CAAD Q36051099-E4081FC5-6DA3-45EA-A48E-17E6E3D91A98 Q36070475-BBEE4366-9FEF-40E4-9682-1FB0DCD760A5 Q36078435-023BBD86-C6A9-40D4-A6CF-3311FFFAC583 Q36143261-FFA44473-6D07-497F-84F7-20EEAD6FA118 Q36169665-8102658F-A9E2-4904-8EE9-7231265246E0 Q36186164-C029FEB5-9AD5-4F34-B3A8-57DB23A19CFE Q36199721-C6694245-1BF6-4486-A216-321FB9DD3036 Q36206122-9334064B-437A-4675-B873-060DD4837D24 Q36353705-E7E772E5-912B-4BAC-9D61-7C6CC63E709B Q36385359-4A7F0946-8CC5-4D1D-9340-51B93767C65B Q36582790-7A52B11B-9BB2-4782-86B2-902E51AAC333 Q36617508-053B014D-48B6-489A-8002-F990A7316779 Q36619746-9BAD7E6C-67D5-45C1-9A5D-F2CD133FC961 Q36672353-77E56223-8D23-4032-B263-4DD753698493 Q36767718-CD106AE8-BA35-46D2-B560-8CC444A4A6FD Q36775577-1CBFD988-2004-4BF2-841F-7A18692BEA2C Q36783613-A90AA959-576A-4A2F-9135-F280A7B435A4 Q36796798-4A54C213-8899-4C15-98A4-33B9978F91EE Q37033749-1ADA8683-1B59-4D75-AEC5-218E5431FD6F Q37087491-36E1F2AF-DF29-4066-A2F0-78EEAE72FD9D Q37108888-1A630FB8-0FB9-4C27-BC3E-2AD3553F2F68 Q37210936-5C4AB157-1E04-4BEA-859C-52B240A009E2 Q37613445-846B8465-7C17-4597-A387-3B53E6DBEA05 Q37662547-B1D5B3D6-5E25-485F-9456-75C88547E715 Q37733136-F8250B9F-C6E9-4D9E-85B8-99B4F1D9A2D8 Q38362373-5332AE2A-C1A0-43FE-A9F0-D6C245290F29 Q38543304-EB17816B-5B68-4F0B-8B35-76C2E8C64768 Q38543320-A73E63B8-F3B4-42B9-9F2D-F910DBFDC17A Q38587540-8C3A7E52-1826-491A-BD7B-309EF63FBF52 Q38604626-FBBFFE4E-C575-4763-98C5-59B23E0B1F51 Q38696998-CD5B8CCD-130A-4934-B202-A7D4A5025C05 Q38742430-C4933A3D-2CC7-41E4-97F3-FBF59CECD996 Q38803235-B24740FE-6098-412C-B062-8C8DC355DDF3

P2860

Factor XI antisense oligonucleotide for prevention of venous thrombosis.

http://www.wikidata.org/entity/Q35200286

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Factor XI antisense oligonucleotide for prevention of venous thrombosis.

@ast

Factor XI antisense oligonucleotide for prevention of venous thrombosis.

@en

type

label

Factor XI antisense oligonucleotide for prevention of venous thrombosis.

@ast

Factor XI antisense oligonucleotide for prevention of venous thrombosis.

@en

prefLabel

Factor XI antisense oligonucleotide for prevention of venous thrombosis.

@ast

Factor XI antisense oligonucleotide for prevention of venous thrombosis.

@en

P1433

Q35200286-B47DA2B1-9CF9-40E8-A8E2-727223561A4C

P1476

Q35200286-AC85B606-55A1-49E7-9096-C8528B88FDF2

P2093

Q35200286-0511DC85-E8E1-431B-9082-E09B85C5ADF6

Q35200286-4B2F7BDF-EC19-4FD3-9215-D5FAA5C58999

Q35200286-4E09EE2A-6587-450C-BD59-CC2A7AB17C08

Q35200286-551DBEB9-4182-466D-8E25-89DE849848D3

Q35200286-7262A7FC-24C1-4414-9153-780D5332F274

Q35200286-C283A1D5-614A-48CF-8200-B6915767D75E

Q35200286-D295DFBF-DA1E-4D59-9223-8B634AF1DCA0

Q35200286-D33AE018-F978-422C-B64E-DBAD01BB22B2

Q35200286-DB619D2D-0A3E-45F7-9B61-024FD0BBA430

Q35200286-F599B880-8D8A-4EF4-B155-295E11110CB0

P2860

Q35200286-02F4C5AD-EFE0-4881-ABB0-39D0A29DE3F4

Q35200286-1FF6BB8E-3141-46F7-BC1B-60D4D31941DD

Q35200286-46B16619-8C74-4C4B-B8FC-04E804C2298A

Q35200286-612516F4-F0AD-4D5F-81FB-16F538B14FA4

Q35200286-64719EFB-5AE0-40A2-990C-8F3A4393B7AD

Q35200286-6665ABAB-FF2B-455D-A2B7-0655CA038D2B

Q35200286-67C1C08E-D3FC-4236-9AC7-9B87E5B30351

Q35200286-6CD0056B-4B0E-4625-A54F-50EEA95F2391

Q35200286-811739F7-1CE5-484E-A273-9EE36AFC1F0B

Q35200286-921EB414-6853-422C-A7C0-0BFA1E8A7A79

P304

Q35200286-1E62928F-496E-436C-BF09-41B0EBCDBED0

P31

Q35200286-1876B34D-92CA-44FC-ACE7-047652D0EE05

P356

Q35200286-7B94C26E-B306-49BB-9067-0A1D3ABBE5D4

P407

Q35200286-7B51C0B5-49E2-49AB-93A5-C73251EBF642

P433

Q35200286-F202C571-FEE4-41B6-888D-C29B239F9977

P478

Q35200286-325F5A1A-E1DD-483D-9E27-4936C22F3850

P577

Q35200286-FB3515B7-2EEA-4E63-8FF7-6605C67C3FAF

P5875

Q35200286-BDE8D3EF-AB9A-4B22-9BE2-B02EBD6E98BA

P698

Q35200286-63EF437A-5E26-4339-9CDF-C47CC340E056

P921

Q35200286-50796898-A6BB-4986-8D62-648DBA0BDB14

P932

Q35200286-5A6B5A57-4D70-4091-855C-9D5C27F321BE

P356

P1433

The New England Journal of Medicine

P1476

Factor XI antisense oligonucleotide for prevention of venous thrombosis.

@en

P2093

Annelise Segers

http://www.w3.org/2001/XMLSchema#string

Brett P Monia

http://www.w3.org/2001/XMLSchema#string

Claudette Bethune

http://www.w3.org/2001/XMLSchema#string

David Gailani

http://www.w3.org/2001/XMLSchema#string

FXI-ASO TKA Investigators

http://www.w3.org/2001/XMLSchema#string

Gary E Raskob

http://www.w3.org/2001/XMLSchema#string

Harry R Büller

http://www.w3.org/2001/XMLSchema#string

Jeffrey I Weitz

http://www.w3.org/2001/XMLSchema#string

Peter Verhamme

http://www.w3.org/2001/XMLSchema#string

Sanjay Bhanot

http://www.w3.org/2001/XMLSchema#string

P2860

Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo

Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation.

Thrombosis: tangled up in NETs.

Triggers, targets and treatments for thrombosis.

Factor XI activation in a revised model of blood coagulation.

A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty.

Idraparinux versus standard therapy for venous thromboembolic disease.

Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI

Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology

P304

232-240

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1405760

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

372

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

269283276

http://www.w3.org/2001/XMLSchema#string

P698

25482425

http://www.w3.org/2001/XMLSchema#string

P921

P932

4367537

http://www.w3.org/2001/XMLSchema#string